Oruka Therapeutics, Inc. ORKA
Super Investor & Insider
1
Fondi che lo detengono
#797
Rank consenso
1.4%
% dei portafogli
$130.8M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Viking Global Investors · Viking Global Investors | 0.37% | — | 2,666,690 | $130.8M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead product, ORKA-001, targets the p19 subunit of interleukin-23 and is in Phase 2 trials for moderate-to-severe psoriasis, featu…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees28
TickerORKA
Statistics
Market Cap$3.52B
Revenue (TTM)—
Net Income-$105.4M
Net Margin—
EPS—
P/E-37.98
P/S—
P/B6.87
EV/EBITDA-27.40
ROE-27.3%
Dividend Yield—
Price$70.11
Data: Twelve Data · Revenue = mcap / P/S